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Abstract. Enantiomerically pure (R,R)-(+)-2,3-diphenylpiperazine with 98% ee was obtained by resolu-
tion of the corresponding racemic mixture using (1S)-(+)-10-camphorsulfonic acid. The partially resolved 
enriched sample of (S,S)-(–)-2,3-diphenylpiperazine with 73% ee was purified to obtain samples of 97% 
ee using different achiral acids via the preparation of either homochiral or heterochiral hydrogen bonded 
aggregates. 
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1. Introduction 
Though several new processes appeared in recent 
years for the asymmetric synthesis of enantiomeri-
cally pure compounds, most of the commercially 
important products are still manufactured via the 
processes of resolution of racemic mixtures. The 
most often used modern methods of resolution of ra-
cemates has recently been reviewed.
1
 In recent 
years, new procedures for the resolution of a variety 
of diamines,2 amino alcohols,
3
 diols
4,5
 and diacids
6
 
have been developed in this laboratory using a range 
of commercially available and less expensive chiral 
resolving agents such as L-(+)-tartaric acid, O,O-
dibenzoyltartaric acid, BINOL/boric acid, L-proline 
and chiral amine/boric acid. Also, a conceptually 
novel method of achieving homogeneity of chirality 
by purification of partially resolved amino alcohols 
and a C2-symmetric chiral diamine via the prepara-
tion of corresponding hydrogen bonded homochiral 
or heterochiral aggregates was reported from this 
laboratory.
7 
Recently, we have reported a novel 
method for the resolution of (±)-2,3-diphenylpipera-
zine using L-(+)-tartaric acid.
8
 Using this method, 
enantiomerically pure 2,3-diphenylpiperazine was 
obtained in two successive operations from racemic 
piperazine. It was of our interest to design a single 
step resolution process to access the enanti-
omerically pure compound of this skeleton which 
has biological importance.9 In this study, we report a 
convenient procedure for the resolution of (±)-2,3-
diphenylpiperazine. 
2. Experimental 
2.1 Synthesis of (±)-2,3-diphenylpiperazine 
(±)-2,3-Diphenylpiperazine was synthesized using 
the previously reported procedure and employed in 
the resolution processes.
8
 
2.2 Resolution of (±)-2,3-diphenylpiperazine 1  
using (1S)-(+)-10-camphorsulfonic acid 2 
The (1S)-(+)-10-camphorsulfonic acid (4⋅65 g, 20 mmol) 
and (±)-2,3-diphenylpiperazine 1 (2⋅4 g, 10 mmol) 
were taken in CH2Cl2 (100 mL) and the contents 
were stirred at 25°C for 24 h and filtered. The pre-
cipitate I was suspended in a mixture of CH2Cl2 and 
aq. Na2CO3 (2M) and stirred until dissolution oc-
curred. The organic layer was separated and the 
aqueous layer was extracted with CH2Cl2 (2 × 10 mL). 
The combined organic extract was washed with brine, 
dried over anhydrous K2CO3. The solvent was evapo-
rated to obtain (R,R)-1. The filtrate I was concen-
trated to reduce its volume by 50 mL and stirred for 
another 12 h and filtered. The precipitate II was 
separated and suspended in a mixture of CH2Cl2 and 
aq. Na2CO3 (2M) and stirred until dissolution oc-
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curred. The organic layer was separated and the 
aqueous layer was extracted with CH2Cl2 (2 × 10 mL). 
The combined organic extract was washed with 
brine, dried over anhydrous K2CO3 and the solvent 
was evaporated to obtain (S,S)-1. The filtrate was 
stirred with aq. Na2CO3 (2M) and stirred for 30 min. 
The organic layer was separated and the aqueous layer 
was extracted with CH2Cl2 (2 × 10 mL). The com-
bined organic extract was washed with brine, dried 
over anhydrous K2CO3 and the solvent was evapo-
rated to obtain (R,R)-1. 
 
Precipitate I 
Yield: 0⋅60 g (25%), mp: 88–90°C, ee: 98% (R,R) 
from HPLC. 
Precipitate II 
Yield: 1⋅50 g (62%), ee: 73% (S, S) from HPLC. 
Fitrate II 
Yield: 0⋅24 g (10%), ee: 80% (R,R) from HPLC. 
2.3 Purificaton of non-racemic 2,3-
diphenylpiperazine 1 using achiral acids 3–5 
The partially resolved (S,S)-(–)-2,3-diphenylpipera-
zine 1 (73% ee, 0⋅12 g, 0⋅5 mmol) was dissolved in 
THF (5 mL) and achiral acid (0⋅3 mmol) was added 
and the contents were stirred at 25°C for 2 h and fil-
tered. The precipitate was suspended in a mixture of 
CH2Cl2 (10 mL) and 2M Na2CO3 (5 mL) and stirred 
until the precipitate is completely dissolved. The  
organic layer was separated and the aqueous layer 
was extracted with CH2Cl2 (2 × 5 mL). The combined 
organic extract was washed with brine (10 mL), 
dried over anhydrous K2CO3 and the solvent was 
evaporated to obtain (S,S)-(–)-1. The filtrate was 
evaporated and the residue was taken in CH2Cl2 
(10 mL) and digested with 2M Na2CO3 (5 mL). The 
organic layer was separated and the aqueous layer 
was extracted with diethyl ether (2 × 5 mL). The 
combined organic extract was washed with brine 
(10 mL), dried over anhydrous K2CO3 and the sol-
vent was evaporated to obtain (S,S)-(–)-1. 
2.4 HPLC analysis of the trifluoroacetamide 
derivatives of 2,3-diphenylpiperazine 
The (±)-2,3-diphenylpiperazine 1 (0⋅5 mmol) in 
CH2Cl2 (10 mL) was stirred overnight with excess 
trifluoroacetic anhydride (TFAA). The solution was 
concentrated under reduced pressure to remove the 
solvent and excess TFAA. The residue was purified 
by flash column chromatography (silicagel 230–400 
mesh, 5% EtOAc/hexanes v/v) or re-crystallized 
from hexane/CH2Cl2 (99
 
:
 
1) mixture. The trifluoro-
acetamide derivative was dissolved in isopropanol 
(~10 mg/mL) and HPLC analyses were performed 
using a Chiralcel OD-H column supplied by Daicel 
Chemical Industries, Ltd with a binary gradient 
method using hexanes:isopropanol (98 :
 
2) in the 
flow rate 0⋅5 mL/min. Retention times for the trifluo-
roacetamide derivatives of 2,3-diphenylpiperazine 
are 10⋅5 min for the (R,R)-1 and 12⋅3 min for the 
(S,S)-1. 
2.5 HPLC analysis of (±)-2,3-diphenylpiperazine 1 
The (±)-2,3-diphenylpiperazine 1 was dissolved in 
isopropanol (~10 mg/mL) and HPLC analyses were 
performed using a Chiralcel OD-H column supplied 
by Daicel Chemical Industries, Ltd with a binary 
gradient method using hexanes:isopropanol (90
 
:
 
10) 
in the flow rate 0⋅5 mL/min. Retention times for the 
enantiomers of (±)-2,3-diphenylpiperazine are 
11⋅8 min for the (S,S)-1 and 14⋅7 min for the (R,R)-1. 
3. Results and discussion 
In the initial studies, effect of the quantity of solvent 
and chiral resolving agent on the outcome of the 
resolution was studied (scheme 1, table 1). When the 
resolution was carried out in THF solvent using 
2⋅25 mmol of (1S)-(+)-10-camphorsulfonic acid (for 
1⋅5 mmol of (±)-2,3-diphenylpiperazine), 58% ee 
was obtained from the filtrate fraction (table 1, entry 
1). Employing 2 equivalents (3⋅0 mmol for 1⋅5 mmol 
of (±)-1 of (1S)-(+)-10-camphorsulfonic acid, the 
enantiopurity was increased to 80% ee, albeit in 
20% yield (table 1, entry 2). When CH2Cl2 was used 
as the solvent, (R,R)-1, with 90% ee was obtained 
from the precipitate fraction and a sample of (S,S)-
(1) with 60% ee was obtained from filtrate fraction 
(table 1, entry 3). 
 
 
 
Scheme 1. 
Resolution of (±)-trans-2,3-diphenylpiperazine using (1S)-(+)-10-camphorsulfonic acid 
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Table 1. Resolution of (±)-2,3-diphenylpiperazine using (1S)-(+)-10-camphorsulfonic acid.a 
 Piperazine 1 obtained from 
 
 Precipitate fraction Filtrate fraction 
 
Entry Piperazine 1 (mmol) CSA 2 (mmol) % eeb/conf Yield (%)c % eeb/conf Yield (%)c 
 
1d 1.5 2.25 50 (R,R) 42 58(S,S) 52 
2d 1.5 3.0  3 (R,R) 75 80(S,S) 20 
3e 1.5 3.0 90 (R,R) 32 60(S,S) 59 
4e,f 10.0 20.0 98 (R,R) 25 73 (S,S) 62 
aAll the reactions were carried out using racemic piperazine 1 and CSA 2 in solvent (10 mL per mmol of piperazine) 
for 12 h. bAll ee values reported here are based on HPLC analysis. cThe yields are of the isolated products, based on 
the total amount of the piperazine 1 used. dTHF was used as solvent. eCH2Cl2 was used as solvent. 
fThe resolution was 
carried out as outlined in scheme 2 
 
 
 
 
Scheme 2. 
 
 
 
Scheme 3. 
 
 
 When the resolution was carried out in 10 mmol 
scale in CH2Cl2 solvent, (R,R)-1 with 98% ee was 
obtained from the precipitate fraction (scheme 2, table 
1, entry 4). In this process, 10 mmol of (±)-2,3-
diphenylpiperazine 1 and 20 mmol of (1S)-(+)-10-
camphorsulfonic acid 2 were taken in CH2Cl2 (100 mL) 
and stirred for 24 h. (R,R)-(+)-2,3-Diphenylpipera-
zine 1, with 98% ee was obtained from precipitate 
fraction I. The filtrate was concentrated to approxi-
mately 50 mL in volume, stirred for another 12 h. 
The precipitate thus formed was separated. From the 
precipitate fraction II, (S,S)-(–)-2,3-diphenylpipera-
zine 1, with 73% ee was obtained in 62% yield. 
(R,R)-(+)-2,3-diphenylpiperazine 1, with 80% ee 
was obtained from filtrate fraction II in 10% yield. 
 
 
Scheme 4. 
 
 
 Recently, a conceptually new method of purifi-
cation of non-racemic samples via the preparation of 
homochiral/heterochiral aggregates was developed 
in our laboratory.
7,8
 This concept is based on the 
formation of homochiral and heterochiral aggregates 
which can be visualized as outlined in the scheme 4 
and scheme 5. Homochiral aggregates are consid-
ered to be aggregates of single enantiomer of chiral 
amine and the achiral acids. The heterochiral salt 
aggregates are formed through the aggregation of 
both isomers of amine and the achiral acids. The 
non-racemic sample can be considered as a combi-
nation of racemic sample and single isomer present 
in excess. In homochiral salt aggregates, the isomer 
present in excess in the non-racemic diamine forms 
aggregates with achiral acid and precipitates out, 
leaving the racemic part in the filtrate fraction 
(scheme 3, table 2, entries 1, 2). 
 In the formation of heterochiral salt aggregates, 
the racemic part in the non-racemic sample forms 
aggregates with achiral acid and precipitates out. 
The isomer present in excess will be left out in the 
filtrate fraction, giving enantiomerically enriched 
product in the filtrate fraction (scheme 4, table 2, en-
tries 3–8). 
 This concept was applied for the enrichment of 
partially resolved non-racemic 2,3-diphenylpipera-
Pothiappan Vairaprakash and Mariappan Periasamy 
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Table 2. Purification of non-racemic 2,3-diphenylpiperazine (S,S)-1 (73% ee) using 
achiral acids.a 
 2,3-Diphenylpiperazine 1 obtained from 
 
 Precipitate fraction Filtrate fraction 
 
Entry Achiral acid % eeb/conf Yield (%)c % eeb/conf Yield (%)c 
 
1 Oxalic acid 97 (S,S) 62 21 (S,S) 31 
2 Malonic acid 94 (S,S) 65 35 (S,S) 33 
3 Fumaric acid 48 (S,S) 58 94 (S,S) 34 
4 Succinic acid 58 (S,S) 50 95 (S,S) 35 
5 Adipic acid 46 (S,S) 51 90 (S,S) 42 
6 Phthalic acid 61 (S,S) 60 82 (S,S) 35 
7 Isophthalic acid 57 (S,S) 58 80 (S,S) 38 
8 Terephthalic acid 63 (S,S) 51 81 (S,S) 40 
aAll the reactions were carried out using non-racemic piperazine (S,S)-1 (73% ee, 
0⋅5 mmol) and achiral acid (0⋅3 mmol) in THF (2 mL) for 2 h. bAll ee values reported here  
are based on HPLC analysis. cThe yields are of the isolated products, based on the total 
amount of the starting non-racemic piperazine used 
 
 
 
 
Scheme 5. 
 
 
zine (S,S)-1 of 73% ee obtained in the resolution 
(scheme 2) using different achiral dicarboxylic acids 
(scheme 5, table 2). Among the achiral acids used, 
oxalic acid 3a and malonic acid 3b gave enanti-
omerically enriched (S,S)-1 up to 95% ee in the pre-
cipitate fraction; in accordance with the predominant 
formation of homochiral salt aggregates in the pre-
cipitate fraction (table 2, entries 1, 2). By using other 
dicarboxylic acids such as fumaric acid 4, succinic 
acid 3c, adipic acid 3d, phthalic acid 5a, isophthalic 
acid 5b and terephthalic acid 5c, enantiomerically 
enriched samples of 1 were obtained in the filtrate 
fraction. In these cases, presumably, heterochiral 
aggregates are formed predominantly in the precipi-
tate fraction, leaving the enantiomerically enriched 
product in the filtrate fraction (table 2, entries 3–8). 
 In order to accomplish the maximum enrichment 
of 1, through the homochiral aggregate enrichment 
process, the amount of achiral acid employed in the 
process should be equivalent to the amount of one of 
the isomers present in excess excluding the racemic 
compound, or less than that. In the case of enrich-
ment of the product through the heterochiral aggre-
gates formation, the amount of achiral acid should 
be equivalent to the racemic part present in the non-
racemic sample or slightly more than that. In this 
case, if the amount of achiral acid is less than that is 
required, the racemic part also will be left out in the 
filtrate fraction, leading to lower enantiomeric purity 
in the filtrate fraction. 
4. Conclusions 
In summary, enantiomerically pure (R,R)-(+)-2,3-
diphenylpiperazine was obtained in 98% ee in a  
single-step operation from the resolution of (±)-2,3-
diphenylpiperazine using (1S)-(+)-10-camphorsulfonic 
acid. Partially resolved (S,S)-(–)-2,3-diphenylpipera-
Resolution of (±)-trans-2,3-diphenylpiperazine using (1S)-(+)-10-camphorsulfonic acid 
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zine (73% ee) obtained from the filtrate fraction in 
the resolution was enriched up to 97% ee using dif-
ferent achiral dicarboxylic acids via the formation of 
homochiral or heterochiral salt aggregates. This  
method of purification of partially resolved samples 
has significant potential for further exploitation in 
large scale chiral processes. 
Acknowledgements 
We are thankful to the ILS-UOH-MOU for a re-
search grant. University Grant Commission (UGC) 
support under the ‘University with Potential for Ex-
cellence (UPE)’ and ‘Centre for Advance Study  
(CAS-SAP)’ programmes is gratefully acknowl-
edged. Award of the JC Bose Fellowship grant to 
MP is gratefully acknowledged. PV is thankful to the 
Council of Scientific and Industrial Research 
(CSIR), Department of Science and Technology (DST) 
and NATCO Pharma for the research fellowship. 
References 
1. Fogassy E, Nogradi M, Kozma D, Egri G, Palovies E  
and Kiss V 2006 Org. Biomol. Chem. 4 3011 
2. Periasamy M, Seenivasaperumal M, Padmaja M and  
Rao V D 2004 Arkivoc viii 4; Satishkumar S and 
Periasamy M 2006 Tetrahedron: Asymmetry 17 1116 
3. Periasamy M, Ramanathan C R and Kumar N S 1999 
Tetrahedron: Asymmetry 10 2307; Periasamy M,  
Kumar N S, Sivakumar S, Rao V D, Ramanathan C R 
and Venkataraman L 2001 J. Org. Chem. 66 3828 
4. Periasamy M, Rao V D and Seenivasaperumal M 2001  
Tetrahedron: Asymmetry 12 1887 
5. Periasamy M, Prasad A S B, Kanth J V B and Reddy 
Ch K 1995 Tetrahedron: Asymmetry 6 341; Periasamy 
M, Venkataraman L, Sivakumar S, Sampathkumar N 
and Ramanathan C R 1999 J. Org. Chem. 64 7643;  
Periasamy M, Reddy M N and Anwar S 2004 Tetrahe-
dron: Asymmetry 15 1809; Periasamy M, Venkatara-
man L and Thomas K R J 1997 J. Org. Chem. 62 4302 
6. Ramanathan C R and Periasamy M 1998 Tetrahedron: 
Asymmetry 9 2651 
7. Periasamy M, Sivakumar S, Reddy M N and Padmaja 
M 2004 Org. Lett. 6 265 
8. Vairaprakash P and Periasamy M 2006 J. Org. Chem. 
71 3636 
9. Tagat, J R; Steensma R W, McCombie S W, Nazareno  
D V, Lin S, Neustadt B R, Cox K, Xu S, Wojcik L, 
Murray M G, Vantuno N, Baroudy B M and Stizki J M 
2001 J. Med. Chem. 44 3343; Zhang Y, Rothman R B, 
Dersch, C M, de Costa B R, Jacobson A E and Rice 
K C 2000 J. Med. Chem. 43 4840; Matecka D,  
Rothman R B Radesca L, de Costa B R, Dersch C M, 
Partilla J S, Pert A, Glowa J R, Wojnicki F H E and 
Rice K C 1996 J. Med. Chem. 39 4704; Glowa J R, 
Fantegrossi W E, Lewis D B, Matecka D, Rice K C 
and Rothman R B 1996 J. Med. Chem. 39 4689; Corey 
E J, Gin D Y and Kania R S 1996 J. Am. Chem. Soc.  
118 9202; Giardina D, Gulini U, Massi M, Piloni M G, 
Pompei P, Rafaiani G and Melchiorre 1993 C J. Med. 
Chem. 36 690; Giardina D, Brasili L, Gregori M, Massi 
M, Picchio M T, Quaglia W and Melchiorre C 1989 J. 
Med. Chem. 32 50; Witiak D T and Trivedi B K 1981 
J. Med. Chem. 24 1329; Manoury P M, Dumas A P and 
Najer H 1979 J. Med. Chem. 22 554; Kekenes-Huskey 
P M, Muegge I, Rauch M, Gustd R and Knapp E W 
2004 Bioorg. Med. Chem. 12 6527 
 
 
